VEGF inhibitors used in advanced cancer are associated with significant macrovascular toxicities, including hypertension, hemorrhage, and thromboembolism, requiring careful clinical management.
No takes yet. Share an insight, caveat, or question.
Heightens vigilance for macrovascular events on VEGF inhibitors; leaves optimal management strategies unresolved without prospective data.
Keefe et al. (2011) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: